<DOC>
	<DOC>NCT01345968</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety and efficacy of preoperative intravenous ferric carboxymaltose in patients with anemia undergoing hip or knee replacement</brief_summary>
	<brief_title>Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>age &gt;= 18 years Patients scheduled to undergo hip or knee replacement 8 g/dl &lt; Hb &lt; 13 g/dl for men and 8 g/dl &lt; Hb &lt; 12 g/dl for women at screening (34 weeks prior to surgery) anemia signed written informed consent immunosuppressive or myelosuppressive therapy history of thromboembolic events a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient hypersensitivity to any component of the formulation transfusion within 1 month prior to study inclusion liver values 3 times higher than normal active severe infection/inflammation renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>transfusion</keyword>
	<keyword>intravenous ferric carboxymaltose</keyword>
</DOC>